Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$135 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
EV/EBITDA
-0.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$0.8
EPS
$-0.6
Face value
--
Shares outstanding
216,998,876
CFO
$-326.85 Mln
EBITDA
$-373.66 Mln
Net Profit
$-381.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tenaya Therapeutics Inc (TNYA)
| -4.3 | 21.2 | -4.3 | 19.5 | -37.9 | -- | -- |
|
BSE Sensex*
| -13.5 | -9.9 | -14.0 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Tenaya Therapeutics Inc (TNYA)
| -50.2 | -55.6 | 61.2 | -89.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tenaya Therapeutics Inc (TNYA)
|
0.7 | 134.5 | 0.0 | -90.6 | -- | -83.8 | -- | 1.1 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated... hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 Read more
CEO, Secretary & Director
Mr. Faraz Ali M.B.A.
CEO, Secretary & Director
Mr. Faraz Ali M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Tenaya Therapeutics Inc (TNYA) is $0.68 (NASDAQ) as of 01-Apr-2026 16:21 EDT. Tenaya Therapeutics Inc (TNYA) has given a return of -37.95% in the last 3 years.
Since, TTM earnings of Tenaya Therapeutics Inc (TNYA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.20
|
0.88
|
|
2024
|
-1.09
|
1.31
|
|
2023
|
-1.93
|
1.72
|
|
2022
|
-0.73
|
0.37
|
|
2021
|
-4.90
|
1.22
|
The 52-week high and low of Tenaya Therapeutics Inc (TNYA) are Rs 2.35 and Rs 0.36 as of 02-Apr-2026.
Tenaya Therapeutics Inc (TNYA) has a market capitalisation of $ 135 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Tenaya Therapeutics Inc (TNYA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.